Skip to main content
. 2022 Jan 22;9(2):ofab651. doi: 10.1093/ofid/ofab651

Figure 1.

Figure 1.

Association between occurrence of KDIGO (Kidney Disease: Improving Global Outcomes) and RIFLE (modified Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) classifications and day 2 vancomycin area under the curve (AUC) with rank-ordered categories of <400, 400–600, and >600 in the primary analysis (n = 230; A) and sensitivity analysis that excluded patients who experienced RIFLE Risk on day 2 of vancomycin (n = 223; B). A, Test for trends: KDIGO stage 1: P = .02; RIFLE Risk: P = .10; KDIGO stage 2/RIFLE Injury: P = .43; KDIGO stage 3/RIFLE Injury: P = .32. B, Test for trends: KDIGO stage 1: P = .01; RIFLE Risk: P = .05; KDIGO stage 2/RIFLE Injury: P = .34; KDIGO stage 3/RIFLE Injury: P = .34.